

Index to Volume Twenty-four

Index of Issues: January, 1-60; February, 61-120; March, 121-180; April, 181-240; May, 241-311; July, 313-386; August, 387-442; September, 443-494; October, 495-554; November, 555-614.

INDEX OF AUTHORS

- A**
- Adjovi C, 109
Aebischer F, 69
Agacfidan A, 573
Ahmet Z, 116
Alary M, 109
Allaire G, 23
Amortegui AJ, 38
Anderson RM, 185
Anderson, L, 347
Angamuthu V, 251
Ankrah EM, 550
Apter D, 343
Aral SO, 185, 299
Arvidson M, 418
Ashley RL, 149
Avgerinou H, 378
- B**
- Badur S, 573
Balamotis A, 469
Barbarash RA, 481
Bearinger LH, 503
Beauvais B, 293
Belongia EA, 251
Berk I, 538
Berge ZA, 121
Berman SM, 169
Beyrer C, 546
Bhadra K, 495
Black CM, 299
Blander SJ, 38
Blank S, 218
Bleker OP, 456
Blythe MJ, 261, 313
Bock JE, 567
Boer K, 456
Bogaerts J, 32
Bolan G, 176, 443, 599
Bollen LJM, 456
Borenstein LA, 422
Borg L, 322
Brizendine EJ, 313
Brome MW, 218
Brookmeyer R, 436
Brunham RC, 387
Buatiang A, 142
Bushar HF, 161
Bwayo J, 267, 387
- C**
- Campbell PJ, 487
Caprilli F, 533
Carey JC, 353
Carlson RG, 204
Carolina J, 511
Carré N, 582
Cates W Jr., 185
Celentano DD, 546
Celum CL, 131, 443, 599
Chaisilwattana P, 495
- Changalucha J, 121
Chearskul S, 495
Chenia HY, 18
Chernesky MA, 61
Chiang CS, 176
Chitwarakorn A, 142
Chotpitayasunondh T, 495
Chow JM, 573
Chuachowong R, 495
Cierns EL, 422
Clarke P, 443, 599
Code K, 599
Conde-Glez CJ, 211
Cordero E, 422
Corey L, 149
Cotch MF, 353
Courtney JG, 422
Couri-Doniger P, 587
Coutinho RA, 363
Coutlée F, 23
Crabbé F, 32
Crescimbeni E, 533
Crowe G, 127
Cuan J, 176
Culpepper-Morgan J, 322
Curtis R, 322
Cyr WH, 161
- D**
- Dailianas S, 469
Dalby DM, 393
Danila RN, 251
Danzig MR, 156
Davo N, 109
de Boer MA, 546
Deák J, 538
DeBoer JM, 251
Degregorio B, 481
Deguchi K, 247
Deguchi T, 247, 284
del Río-Chiriboga C, 211
DeLisle S, 131
Des Jarlais DC, 320, 322
Desmyter J, 94
Dewet GH, 94
Diakomanolis E, 469
Diallo M, 32
Dicker LW, 511
Dixon LG, 161
Dixon, PB, 229
Donders G, 94
Dorian KJ, 169
Douglas JM, 555
Douglas JM, Jr, 429
duBouchet L, 156
Dussaix E, 582
Dyer IE, 422
- E**
- Edelman R, 353
Ehret JM, 429
Eschenbach DA, 353
- F**
- Falck RS, 204
Farley TA, 227
Faulkner PL, 503
Fennema JSA, 363
Fife KH, 481, 555
Fine D, 131
Finnish Study Group For Antimicrobial Resistance, 576
Flemetakis A, 378
Fonseca K, 487
Ford K, 327
Forster GE, 127
Fortenberry JD, 261, 313, 555
Fox R, 436
Frangouli E, 378
Fresia A, 402
Frey RL, 461
Friedman LS, 90
Friedman SR, 322
- G**
- Garnett GP, 45, 185
Gentili G, 533
Germaine M, 109
Ghadirian P, 23
Ghani AC, 45
Ghattas G, 23
Ghys P, 32
Gibbs RS, 353
Giglio A, 533
Ginsberg MM, 347
Giuliani M, 533
Goh BT, 127
Grant I, 398
Greenspan JR, 218
Gross TP, 11
Grosskurth H, 121
Guèdèmè A, 109
Gunn RA, 90
- H**
- Haddix A, 287
Handsfield HH, 131, 272, 449
Harvey SM, 422
Hayasaki M, 284
Heaton RK, 398
Hellberg D, 241, 418
Henry K, 443, 599
Hernández-Avila M, 211
Hernández-Nevárez P, 211
Herne K, 555
Hickman CD, 251
Hillier SL, 353
Hillis SD, 131
Hiltunen-Back E, 165
Hirvonen S, 343
Hollins L, 475
Holmes KK, 561
Hooft P, 94
Hook EW III, 181, 229, 599, 372, 436, 443
- Hoosen AA, 18
Houang ET, 116
Howell MR, 287
Hoyle DV, 185
Hughes JP, 272, 449
Huovinen P, 576
Hwang L-Y, 475
- I**
- Iida M, 284
Irwin DE, 372
Iwasawa A, 165
- J**
- Jackson D, 267
Jacobs B, 121
Jadack RA, 402
Jahkola M, 576
Järvinen H, 576
Joly JR, 109
Jose B, 322
Juárez-Figueroa LA, 211
Judson FN, 429
- K**
- Ka-Gina G, 121
Kallings I, 418
Kalogeropoulou A, 378
Kalpaktoglou K, 469
Kanematsu E, 247
Kassler WJ, 287
Katz BP, 313
Katz MH, 347
Kaul R, 387
Kawada Y, 247, 284
Kellogg T, 347
Kilmarx PH, 593
Kimani J, 387
Kjaer SK, 567
Klebanoff MA, 353
Knapp JS, 2, 142
Komeda H, 284
Korattana S, 593
Koutsky L, 149
Kovács L, 538
Kreek MJ, 322
Kreiss JK, 267, 279
Krohn MA, 353
Krone M, 599
Ku L, 299
Kyriakis KP, 378
- L**
- Labropoulou V, 469
Lafferty WE, 272, 449
Laga M, 32
Landis SJ, 393
Lawlor JP, 436
Lawrence AG, 116
Leduc R, 23
Leonard L, 475
Leone P, 443

Index to Volume Twenty-four

Index of Issues: January, 1-60; February, 61-120; March, 121-180; April, 181-240; May, 241-311; July, 313-386; August, 387-442; September, 443-494; October, 495-554; November, 555-614.

INDEX OF AUTHORS

- A**
- Adjovi C, 109
Aebischer F, 69
Agacfidan A, 573
Ahmet Z, 116
Alary M, 109
Allaire G, 23
Amortegui AJ, 38
Anderson RM, 185
Anderson, L, 347
Angamuthu V, 251
Ankrah EM, 550
Apter D, 343
Aral SO, 185, 299
Arvidson M, 418
Ashley RL, 149
Avgerinou H, 378
- B**
- Badur S, 573
Balamotis A, 469
Barbarash RA, 481
Bearinger LH, 503
Beauvais B, 293
Belongia EA, 251
Berk I, 538
Berge ZA, 121
Berman SM, 169
Beyrer C, 546
Bhadra K, 495
Black CM, 299
Blander SJ, 38
Blank S, 218
Bleker OP, 456
Blythe MJ, 261, 313
Bock JE, 567
Boer K, 456
Bogaerts J, 32
Bolan G, 176, 443, 599
Bollen LJM, 456
Borenstein LA, 422
Borg L, 322
Brizendine EJ, 313
Brome MW, 218
Brookmeyer R, 436
Brunham RC, 387
Buatiang A, 142
Bushar HF, 161
Bwayo J, 267, 387
- C**
- Campbell PJ, 487
Caprilli F, 533
Carey JC, 353
Carlson RG, 204
Carolina J, 511
Carré N, 582
Cates W Jr., 185
Celentano DD, 546
Celum CL, 131, 443, 599
Chaisilwattana P, 495
- Changalucha J, 121
Chearskul S, 495
Chenia HY, 18
Chernesky MA, 61
Chiang CS, 176
Chitwarakorn A, 142
Chotpitayasunondh T, 495
Chow JM, 573
Chuachowong R, 495
Cierns EL, 422
Clarke P, 443, 599
Code K, 599
Conde-Glez CJ, 211
Cordero E, 422
Corey L, 149
Cotch MF, 353
Courtney JG, 422
Couri-Doniger P, 587
Coutinho RA, 363
Coutlée F, 23
Crabbé F, 32
Crescimbeni E, 533
Crowe G, 127
Cuan J, 176
Culpepper-Morgan J, 322
Curtis R, 322
Cyr WH, 161
- D**
- Dailianas S, 469
Dalby DM, 393
Danila RN, 251
Danzig MR, 156
Davo N, 109
de Boer MA, 546
Deák J, 538
DeBoer JM, 251
Degregorio B, 481
Deguchi K, 247
Deguchi T, 247, 284
del Río-Chiriboga C, 211
DeLisle S, 131
Des Jarlais DC, 320, 322
Desmyter J, 94
Dewet GH, 94
Diakomanolis E, 469
Diallo M, 32
Dicker LW, 511
Dixon LG, 161
Dixon, PB, 229
Donders G, 94
Dorian KJ, 169
Douglas JM, 555
Douglas JM, Jr, 429
duBouchet L, 156
Dussaix E, 582
Dyer IE, 422
- E**
- Edelman R, 353
Ehret JM, 429
Eschenbach DA, 353
- F**
- Falck RS, 204
Farley TA, 227
Faulkner PL, 503
Fennema JSA, 363
Fife KH, 481, 555
Fine D, 131
Finnish Study Group For Antimicrobial Resistance, 576
Flemetakis A, 378
Fonseca K, 487
Ford K, 327
Forster GE, 127
Fortenberry JD, 261, 313, 555
Fox R, 436
Frangouli E, 378
Fresia A, 402
Frey RL, 461
Friedman LS, 90
Friedman SR, 322
- G**
- Garnett GP, 45, 185
Gentili G, 533
Germaine M, 109
Ghadirian P, 23
Ghani AC, 45
Ghattas G, 23
Ghys P, 32
Gibbs RS, 353
Giglio A, 533
Ginsberg MM, 347
Giuliani M, 533
Goh BT, 127
Grant I, 398
Greenspan JR, 218
Gross TP, 11
Grosskurth H, 121
Guèdèmè A, 109
Gunn RA, 90
- H**
- Haddix A, 287
Handsfield HH, 131, 272, 449
Harvey SM, 422
Hayasaki M, 284
Heaton RK, 398
Hellberg D, 241, 418
Henry K, 443, 599
Hernández-Avila M, 211
Hernández-Nevárez P, 211
Herne K, 555
Hickman CD, 251
Hillier SL, 353
Hillis SD, 131
Hiltunen-Back E, 165
Hirvonen S, 343
Hollins L, 475
Holmes KK, 561
Hooft P, 94
Hook EW III, 181, 229, 599, 372, 436, 443
- Hoosen AA, 18
Houang ET, 116
Howell MR, 287
Hoyle DV, 185
Hughes JP, 272, 449
Huovinen P, 576
Hwang L-Y, 475
- I**
- Iida M, 284
Irwin DE, 372
Iwasawa A, 165
- J**
- Jackson D, 267
Jacobs B, 121
Jadack RA, 402
Jahkola M, 576
Järvinen H, 576
Joly JR, 109
Jose B, 322
Juárez-Figueroa LA, 211
Judson FN, 429
- K**
- Ka-Gina G, 121
Kallings I, 418
Kalogeropoulou A, 378
Kalpaktoglou K, 469
Kanematsu E, 247
Kassler WJ, 287
Katz BP, 313
Katz MH, 347
Kaul R, 387
Kawada Y, 247, 284
Kellogg T, 347
Kilmarx PH, 593
Kimani J, 387
Kjaer SK, 567
Klebanoff MA, 353
Knapp JS, 2, 142
Komeda H, 284
Korattana S, 593
Koutsky L, 149
Kovács L, 538
Kreek MJ, 322
Kreiss JK, 267, 279
Krohn MA, 353
Krone M, 599
Ku L, 299
Kyriakis KP, 378
- L**
- Labropoulou V, 469
Lafferty WE, 272, 449
Laga M, 32
Landis SJ, 393
Lawlor JP, 436
Lawrence AG, 116
Leduc R, 23
Leonard L, 475
Leone P, 443

Leone P, 599
 Leone PA, 372
 Lepri AC, 533
 LeRoux T, 429
 Levine WC, 169
 Liimatainen O, 576
 Limpakarnjanarat K, 142, 593
 Lytle CD, 161

M

MacDonald KL, 251
 MacEachern A, 84
 MacLean I, 267
 Magnus P, 102
 Mahony JB, 109
 Maini A, 533
 Malone JL, 398
 Manalastas TR, 2
 Mandaliya K, 267, 279
 Mangclaviraj Y, 495
 Mårdh P-A, 418, 241
 Marrazzo JM, 131
 Martin DH, 353, 372
 Martin HL Jr, 279
 Maruti S, 475
 Masterson MB, 218
 Mastro TD, 142, 495, 593
 Mavromara P, 469
 Mayaud P, 121
 Mbengeranwa L, 528
 McCombs SB, 461
 McCormack M, 156
 McCormack WM, 361, 543
 McCray E, 461
 McCutchan JA, 398
 McDonnell DD, 218
 McDougall JK, 69
 McNicol P, 293
 Meng CY, 257
 Mertz KJ, 169
 Mesola VP, 2
 Mészáros G, 538
 Meyer L, 582
 Miller HG, 522
 Miller LK, 398
 Mol BW, 456
 Montstream SA, 429
 Morgan SC, 236
 Moses S, 267
 Mosure DJ, 169
 Munk C, 567
 Munyabikali J, 32

N

Nagatani M, 284
 Nagelkerke NJD, 387
 Nagy E, 538
 Nakano M, 247
 Ndinya-Achola J, 267, 279
 Ndowa F, 528
 Neaigus A, 322
 Neal JJ, 218
 Neal SW, 2, 142
 Nelson J, 398
 Nelson KE, 546
 Ngugi EN, 387
 Nieminen P, 165
 Nilsson S, 241, 418

Nilsson U, 241
 Nishino Y, 247
 Nissinen A, 576
 Norris, A, 327
 Nugent RP, 353
 Nuntakuang D, 546
 Nyange PM, 279
 Nyári T, 538
 Nzila N, 32

O

Obongo T, 267
 Oldfield EC, III, 398
 Onorato IM, 461
 Orr DP, 261, 313
 Ortiz CG, 429
 Osterholm MT, 251
 Ozarmagan G, 573
 Ozeki S, 247

P

Paavonen J, 165, 343
 Padonou F, 109
 Paffel J, 475
 Palamara G, 533
 Paone D, 322
 Parekh MC, 142
 Parks KS, 229
 Pashazade H, 573
 Pastorek JG II, 353
 Pauku M, 343
 Peek M, 8
 Perine PL, 2
 Peterman TA, 511
 Pickard L, 393
 Pickering J, 543
 Pillay B, 18
 Pillay D, 18
 Plummer FA, 387
 Poll P, 567
 Potterat JJ, 519
 Potthoff SJ, 503
 Preiksaitis JK, 487
 Prematurity Study Group, 353
 Prignano G, 533
 Puolakkainen M, 343

Q

Quinn TC, 436

R

Rakwar J, 267
 Rand S, 436
 Rao AV, 353
 Regan JA, 353
 Reichman RC, 587
 Rein MF, 156
 Remafedi GJ, 503
 Resnick MD, 503
 Reunala T, 165
 Rezza G, 533
 Rhoads GG, 353
 Richardson BA, 279
 Richey CM, 229, 443
 Rietwald GA, 422
 Rietmeijer CA, 429
 Robain M, 582

Roberts MC, 561
 Rodrigues I, 23
 Romanowski B, 487
 Rompalo AM, 402, 436
 Ronald A, 387
 Ross M, 475
 Roth R, 481
 Rothenberg R, 201
 Routson LB, 161
 Rubin SR, 218
 Rudolph T, 481
 Rugamba D, 279
 Rugpao S, 546

S

Sadler R, 181
 Safrin S, 176
 Saito I, 247
 Salmon-Ceron D, 582
 Sanche G, 23
 Sato K, 247
 Saurina GR, 361
 Schachter J, 1
 Schwarcz SK, 347
 Schwartz MA, 449
 Schwebke JR, 181, 236, 372
 Seaborn GB, 161
 Sellors JW, 393
 SEROCO Study Group, 582
 Shaffer N, 495
 Sharma R, 543
 Shaw H, 176
 Shepherd M, 436
 Shew ML, 503
 Shoubnikova M, 241
 Siegal HA, 204
 Silverman BG, 11
 Siriwasin W, 495
 Smith H, 267
 Smith M, 443, 599
 Sokal D, 550
 Sonenstein FL, 299
 Spalding C, 443, 599
 Spence MR, 156
 Spitters C, 347, 372
 St Louis ME, 593
 Stevens CE, 279
 Stevenson E, 84
 Stigum H, 102
 Stratton JD, 372
 Sturm AW, 64
 Suan KA, 257
 Suligoi B, 77
 Supavitkul S, 593
 Sutton JM, 181
 Svare EI, 567
 Swinton J, 45

T

Tanaka M, 247
 Taylor BA, 503
 ten Kate FJW, 456
 ter Schegget J, 456
 Termorshuizen F, 334
 Theodore C, 127
 Thomas JC, 372
 Thompson SC, 84
 Tjong-A-Hung SP, 456
 Todd J, 121

Toma E, 23
 Toomey KE, 511
 Tovanabutra S, 546
 Trotter A, 23
 Tuazon, C, 2
 Turmel B, 23
 Turner CF, 299, 522
 Tying SK, 555
 Tzelepi E, 378
 Tzouveleakis LS, 378

U

Uno M, 284
 Urban MA, 587
 Uribe-Salas FJ, 211
 Uribe-Zúñiga P, 211

V

Vaginal Infections and
 Valaciclovir International Herpes
 Simplex Virus Study
 Group, 481
 Van Ameijden EJC, 363
 van de Laar MJW, 334, 409
 van den Hoek A, 334, 363
 van der Meijden WI, 409
 van der Velden J, 456
 van Duynhoven YTHP, 409
 Van Dyck E, 32, 109
 Van Klingeren B, 409
 van Santen-Verheul MG, 409
 Veinbergs E, 90
 Velin R, 398
 Veréb I, 538
 Vongchak T, 546

W

Wald A, 149
 Wallace MR, 398
 Wang J, 204
 Weiss HL, 236
 Weiss PJ, 398
 Wellington M, 528
 Whittington WL, 2, 561
 Wi TE, 2
 Wongba C, 142
 Wroten JE, 511

X

Xia M, 561

Y

Yamaguchi KJ, 429
 Yasin RM, 257
 Yasuda M, 247
 Young NL, 142, 495, 293
 Yutaboot Y, 546

Z

Zaidi AA, 511
 Zenilman J, 8, 310, 322, 372, 402,
 436
 Zenilman JM, 310, 372
 Zimet GD, 555

A

- Aboriginal women, HPV infection in, vs. in non-Aboriginal women, in Canada, 293
- Adolescents
- female, validity of self-reported sexual behavior in, 261
 - minority, sexual networks of, 327
 - prevention measures for, 90
 - substance use and sexual behavior in
 - in females, 313, 320 (editorial)
 - in high-risk neighborhoods, 322
 - validity of self-reported condom use in, 503
- Africa
- Kenya
 - female sex workers in, safety of nonoxynol-9 vaginal gel in, 279
 - genital ulcer disease in, in prostitutes, 387
 - truck drivers in, *H. ducreyi* antibody in, 267
 - N. gonorrhoeae* drug resistance in, 11, 32
 - Tanzania, sexual transmission of hepatitis B in, 121
 - Zimbabwe, STD risk factors in, 528
- African Americans
- adolescent, sexual networks of, 327
 - gestational trichomoniasis in, low birth weight and preterm delivery and, 353
 - motivation for HIV testing in, 347
- AIDS dementia, STD history and, 398
- Alcohol use/abuse, sexual behavior and, in female adolescents, 313, 320 (editorial)
- Allantoin, in AVC suppositories, for trichomoniasis, vs. oral metronidazole, 156
- Aminacrine, in AVC suppositories, for trichomoniasis, vs. oral metronidazole, 156
- Anal intercourse, condoms in, 11
- Antibiotics. *See* Antimicrobials
- Anti-HBc, in HIV test seekers, 211
- Antimicrobial resistance. *See* Drug resistance/susceptibility
- Antimicrobials
- resistance to. *See* Drug resistance/susceptibility
 - for syphilis, 227 (editorial)
- Australia, notification of chlamydial infection in, 84
- AVC suppositories, for trichomoniasis, vs. oral metronidazole, 156
- Azithromycin
- N. gonorrhoeae* susceptibility to, E-test vs. agar dilution methods for, 257
 - for nongonococcal urethritis, 57 (letter)

B

- Bacterial vaginosis, self-obtained sequential vaginal smears for, utility of, 236
- Behavioral surveys, with integrated STD testing, 299, 552 (letter)
- Benzathine penicillin, single injection of, for syphilis, in pregnancy, 94

C

- Canada
- HIV seroprevalence in, risk behaviors and, 487
 - HPV infection in Aboriginal vs. non-Aboriginal women in, 293
 - physicians' management of STDs in, 393
- Cancer, cervical, type-specific prevalence of HPV in, in Greece, 469
- Casual travel sex, high-risk behavior and, 418
- Central Africa, *N. gonorrhoeae* resistance in, 32
- Cervical cancer, type-specific prevalence of HPV in, in Greece, 469
- Cervical dysplasia, treatment of, clearance of HPV infection by, 456
- Cervical *Mycoplasma genitalium*, in Japan, 284
- Chancroid, *H. ducreyi* virulence in, iron and, 64
- Chlamydia trachomatis* infection

- interferon-gamma and interleukin-5 in, 38
- in low-risk population, in Hungary, 538
- notification of, in Australia, 84
- partner notification for, for PID prevention, 287
- partner referral by patients with, 334
- PCR test for, urine tests for, 343, 429
- in pregnant women, in Thailand, 495
- prevalence trends for, 169
- screening for
- algorithm for, for high-risk groups in developing countries, 109
 - in men, 587
 - noncompliance with follow-up recommendations after, 181
 - performance and cost-effectiveness of, 131
 - in Turkish sex workers, 573
- sexual behavior risk factors for, 241
- spontaneous clearance of, in untreated patients, 229
- surveillance of, laboratory compliance and, 84
- Ciprofloxacin, *N. gonorrhoeae* resistance to, in Philippines, 2
- Clinic patients. *See* also Sexually transmitted disease clinics
- delayed treatment-seeking by, 443
 - motivation for HIV testing in, 347
- Clotrimazole, topical, for trichomoniasis, vs. oral metronidazole, 156
- Cocaine, condom use and, 204
- Cognitive impairment, in HIV infection, STD history and, 398
- Commercial sex workers
- chlamydial infection in, screening for, in Turkey, 573
 - drug-using, STD incidence trends for, 363
 - gonorrhea/chlamydia screening algorithm for, in developing countries, 109
- Kenyan
- genital ulcer disease in, 387
 - safety of nonoxynol-9 vaginal gel in, 279
 - multiple condom use by, in Thailand, 546, 550 (editorial)
 - self-medication for STDs in, in Thailand, 593
- Compliance, with daily procaine penicillin injections, for syphilis-treponemal infection, 127
- Condoms
- in anal intercourse, 11
 - failure to use, reasons for, 402
 - multiple, use of, 550 (editorial)
 - by commercial sex workers, in Thailand, 546, 550 (editorial)
 - self-reported use of, validity of, 522
 - in adolescents, 503
 - as small virus barriers, 161
 - use of by heterosexual drug users, 204
- Condylomata acuminata. *See* also Human papillomavirus infection
- in females, risk factors for, 567
 - in males, HPV DNA in urine in, 165
- Contact tracing. *See* Partner notification
- Crack cocaine, condom use and, 204
- Cultures
- vs. DNA probe test, for *N. gonorrhoeae*, 422
 - organotypic raft, in evaluation of vaginal microbicidal agents, 69
 - virus, vs. PCR, for HSV infection diagnosis, 176
- Cytomegalovirus, seropositivity for, in HIV-infected men, sexual behavior and, 582

D

- Dementia, AIDS, STD history and, 398
- Developing countries. *See* also specific countries
- screening algorithm for gonorrhea and chlamydia in, 109
 - STDs in, public-private initiatives for, 61 (editorial)
- DNA probe test, vs. culture, for *N. gonorrhoeae*, 422
- Drug abuse. *See* Substance use/abuse
- Drug resistance/susceptibility, of *N. gonorrhoeae*, 247

in Finland, 573
 in Greece, 378
 molecular epidemiology and, 409
 in Philippines, 2
 in South Africa, 11
 in Thailand, 142
 in West and Central Africa, 32

E

East Africa, sexual transmission of hepatitis B in, 121
 Estrogen replacement therapy, trichomoniasis and, 543
 E test, for *N. gonorrhoeae* susceptibility to azithromycin, 257

F

Fellatio
 acquisition of gonorrhea and nongonococcal urethritis by, in male homosexuals, 272
 acquisition of nongonococcal urethritis by, in heterosexual males, 449
 Female sex workers. *See Commercial sex workers*
 Field studies, new paradigms for, 310 (editorial)
 Finland, *N. gonorrhoeae* drug resistance in, 576
 First-void urine PCR test, for *C. trachomatis*, 343
 Fluoroquinolones, *N. gonorrhoeae* resistance to, 247
 in Philippines, 2
 in Thailand, 142

G

Gay men, acquisition of gonorrhea and nongonococcal urethritis by fellatio in, 272
 Genital herpes. *See Herpes simplex virus infection*
 Genital ulcer disease
 HIV infection risk and, 436
 in Kenyan prostitutes, 387
 Genital warts. *See also Human papillomavirus infection*
 in females, risk factors for, 567
 in males, HPV DNA in urine in, 165
 Gonococcal cervicitis, in pregnant women, in Thailand, 495
 Gonococcal infection. *See also Gonorrhea; Neisseria gonorrhoeae*
 molecular epidemiology of, 409
 Gonorrhea. *See also Neisseria gonorrhoeae*
 epidemiology of, sexual partnership networks in, 45
 in male homosexuals, acquisition of by fellatio, 272
 molecular epidemiology of, 409
 partner referral by patients with, 334
 screening for
 algorithm for, for high-risk groups in developing countries, 109
 noncompliance with follow-up recommendations after, 181
 Greece
N. gonorrhoeae antimicrobial sensitivity in, 378
 type-specific prevalence of genital HPV in, 469

H

Haemophilus ducreyi
 antibody to, in Kenyan truck drivers, 267
 virulence of, iron and, 64
 HBsAG, in HIV test seekers, 211
 Hepatitis B
 markers of, among male HIV test seekers, 211
 sexual transmission of
 in Mexico, 211
 in Tanzania, 121
 Hepatitis C, in STD high-risk population, 533
 Herpes simplex virus infection

demographic and sexual correlates of, 149
 diagnosis of, virus culture vs. PCR for, 176
 first-episode, Valacyclovir vs. acyclovir for, 481
 immunization for, acceptability of, 555
 High-risk behavior. *See also Risk factors; Sexual behavior*
 in women with history of casual travel sex, 418
 Hispanic adolescents, sexual networks of, 327
 Homosexuals, male, acquisition of gonorrhea and nongonococcal urethritis by fellatio in, 272
 Hormone replacement therapy, trichomoniasis and, 543
 Human immunodeficiency virus infection
 cytomegalovirus seropositivity in, sexual behavior and, 582
 hepatitis B and, 211
 natural history of, in women vs. men, 77
 neurocognitive impairment in, STD history and, 398
 oral HPV infection in, 23
 perinatal transmission of, maternal chlamydial and gonococcal cervicitis and, 495
 persons at high risk for, sexual behavior of partners of, 461
 seroprevalence of, risk behaviors and, in Canada, 487
 STD incidence and risk factors in, 251
 testing for, in STD clinic population, 347
 type 1, genital ulcer disease and, in Kenyan sex workers, 387
 Human papillomavirus
 exposure to, genital warts as marker of, 567
 type-specific prevalence of, in Greece, 469
 Human papillomavirus DNA, in urine of males with condyloma acuminatum, 567
 Human papillomavirus infection. *See also Genital warts*
 in Aboriginal vs. non-Aboriginal Canadian women, 293
 after treatment for cervical dysplasia, 456
 Hungary, chlamydial infection in, in low-risk population, 538

I

Immunization, for genital herpes, acceptability of, 555
 Infant, low birth weight, trichomoniasis and, 353
 Intercourse. *See also Sexual behavior*
 anal, condoms in, 11
 Interferon-gamma, in chlamydial infection, 38
 Interleukin-5, in chlamydial infection, 38
 International Union Against Sexually Transmitted Infections, 606
 Intravenous drug abuse. *See also Substance use/abuse*
 condom use and, 204
 Iron, *H. ducreyi* virulence and, 64

J

Japan, cervical *Mycoplasma genitalium* in, 284

K

Kanamycin, *N. gonorrhoeae* resistance to, in Thailand, 142
 Kenya
 female sex workers in
 genital ulcer disease in, 387
 safety of nonoxynol-9 vaginal gel in, 279
 truck drivers in, *H. ducreyi* antibody in, 267

L

Laboratory compliance, with chlamydia notification requirements, in Australia, 84
 Low birth weight, trichomoniasis and, 353

M

Markers, for hepatitis B, in HIV test seekers, 211
 Mathematical models, utility of, 201 (editorial)
 Menopause, estrogen replacement therapy in, trichomoniasis and, 543
 Metronidazole

- oral, for trichomoniasis, vs. clotrimazole vaginal tablets and AVC suppositories, 156
- with zinc sulfate douche, for trichomoniasis, 116
- Mexico, hepatitis B markers in HIV test seekers in, 211
- Minority adolescents, sexual networks of, 327
- Mycoplasma genitalium*, cervical, in Japan, 284

N

- Neisseria gonorrhoeae*. See also *Gonorrhea*
 - AHUA-1.2 phenotype of, genomic heterogeneity of, 561
 - azithromycin susceptibility testing for, E-test vs. agar dilution methods for, 257
 - DNA probe test vs. culture for, 422
 - drug resistance/susceptibility of, 247
 - in Finland, 576
 - in Greece, 378
 - molecular epidemiology and, 409
 - in Philippines, 2
 - in South Africa, 11
 - in Thailand, 142
 - in West and Central Africa, 32
 - in pregnant women, in Thailand, 495
- Neonate, low birth weight, trichomoniasis and, 353
- Networks
 - in gonorrhea epidemiology, 45
 - of minority adolescents, 327
 - STD reporting and, 552 (letter)
- Neurocognitive impairment, in HIV infection, STD history and, 398
- Neurosyphilis, daily procaine penicillin for, compliance with, 127
- Noncompliance, after positive screening for gonorrhea and chlamydia, 181
- Nongonococcal urethritis
 - azithromycin for, 57 (letter)
 - in heterosexual men, risk factors for, 449
 - in male homosexuals, acquisition of by fellatio, 272
- Nonoxynol-9 vaginal gel, safety of, in Kenyan prostitutes, 279
- Notification
 - for chlamydial infection, in Australia, 84
 - partner
 - cost-benefit ratio for, 511, 519 (editorial)
 - for PID prevention, 287
 - for syphilis, 511, 519 (editorial)

O

- Ofloxacin, *N. gonorrhoeae* resistance to, 247
- Oral human papillomavirus infection, risk factors for, 23
- Organotypic raft cultures, in evaluation of vaginal microbicidal agents, 69

P

- Pap smear, abnormal, genital warts and, 567
- Partner networks, of minority adolescents, 327
- Partner notification
 - cost-benefit ratio for, 511, 519 (editorial)
 - for PID prevention, 287
 - for syphilis, 511, 519 (editorial)
- Partner referral, by patients with gonorrhea and chlamydial infection, 334
- Pelvic inflammatory disease (PID), prevention of, partner notification for, 287
- Penicillin
 - daily injection of, for syphilis-treponemal infection, compliance with, 127
 - N. gonorrhoeae* resistance to. See *Neisseria gonorrhoeae*, drug resistance/susceptibility of
 - single injection of, for syphilis, in pregnancy, 94
- Phillippines, drug-resistant *N. gonorrhoeae* in, 2
- Physicians, STD management by, in urban Canadian center, 393

- Polymerase chain reaction (PCR)
 - for *C. trachomatis*, urine tests for, 343, 429
 - vs. virus culture, for HSV infection diagnosis, 176
- Pregnancy
 - chlamydial and gonococcal cervicitis in, in Thailand, 495
 - syphilis in, single benzathine penicillin injection for, 94
 - trichomoniasis in, 361 (editorial)
 - low birth weight and preterm delivery and, 353
- Preterm delivery, trichomoniasis and, 353
- Prisoners, female, syphilis control for, 218
- Procaine penicillin, daily injection of, for syphilis-treponemal infection, compliance with, 127
- Prostitutes. See *Commercial sex workers*

R

- Race
 - adolescent sexual networks and, 327
 - STD reporting and, 552 (letter)
 - trichomoniasis in pregnancy and, 353
- Raft cultures, in evaluation of vaginal microbicidal agents, 69
- Rapid plasma reagin (RPR) test, for syphilis, in female prisoners, 218
- Reporting
 - of chlamydial infection, in Australia, 84
 - of STDs, race and, 552 (letter)
- Risk factors
 - for bacterial vaginosis, 241
 - for chlamydial infection, 241
 - for HIV infection, genital ulcer disease as, 436
 - for nongonococcal urethritis, 449
 - for oral HPV infection, 23
 - residence in high-risk neighborhood as, 322
 - for STDs, 102
 - in HIV infection, 251
 - in Zimbabwe, 528
 - substance use as, in female adolescents, 313, 320 (editorial)
- Risk index, for STDs, 102

S

- Screening
 - for adolescents, 90
 - for chlamydial infection
 - algorithm for, for high-risk groups in developing countries, 109
 - in men, 587
 - noncompliance with follow-up recommendations after, 181
 - performance and cost-effectiveness of, 131
 - in Turkish sex workers, 573
 - for gonorrhea
 - algorithm for, for high-risk groups in developing countries, 109
 - noncompliance with follow-up recommendations after, 181
 - for syphilis, 227 (editorial)
- Self-treatment, of STDs, 372
 - in Thai sex workers, 593
- Sex, casual travel, high-risk behavior and, 418
- Sexual behavior. See also *Risk factors*
 - assessment of, in adolescents, 90
 - high-risk, in women with history of casual travel sex, 418
 - HIV seroprevalence and, in Canada, 487
 - male, CMV seropositivity in HIV infection and, 582
 - of partners of persons at high risk for HIV infection, 461
 - self-reporting of by female adolescents, validity of, 261
 - substance use and
 - in female adolescents, 313, 320 (editorial)
 - in high-risk neighborhoods, 322
 - surveys of, with integrated STD testing, 299, 552 (letter)
- Sexual intercourse, anal, condoms in, 11
- Sexually transmitted disease clinic patients, motivation for HIV testing in, 347
- Sexually transmitted disease clinics

- delayed presentation to, 443
 use of and need for, 599
- Sexually transmitted diseases (STDs).** *See also specific diseases*
 delayed presentation to clinics in, 443
 in developing countries, public-private initiatives for, 61 (editorial)
 in drug-using prostitutes, incidence trends for, 363
 high-risk population for, hepatitis C in, 533
 HIV-related neurocognitive impairment and, 398
 incidence and risk factors for, in HIV infection, 251
 oral HPV infection as, 23
 physicians' management of, in urban Canadian center, 393
 prevention of, in adolescents, 90
 reporting of, sexual network data and, 552 (letter)
 risk factors for, in Zimbabwe, 528
 risk index for, 102
 self-treatment of, 372
 in Thai sex workers, 593
 surveillance and field studies of, new paradigms for, 310 (editorial)
 tuberculosis and, 8
 urine tests for, integrated with behavioral surveys, 299, 552 (letter)
- Sexually Transmitted Diseases, increased number of issues of, 1 (editorial)*
- Sexual networks**
 in gonorrhea epidemiology, 45
 of minority adolescents, 327
 STD reporting and, 552 (letter)
- Sex workers.** *See Commercial sex workers*
- South Africa, *N. gonorrhoeae* antibiotic susceptibility in, 11**
- Substance use/abuse**
 condom use and, 204
 sexual behavior and
 in female adolescents, 313, 320 (editorial)
 in high-risk neighborhoods, 322
- Sulfanilamide, in AVC suppositories, for trichomoniasis, vs. oral metronidazole, 156**
- Surveillance studies, new paradigms for, 310 (editorial)**
- Surveys, behavioral, with integrated STD testing, 299, 552 (letter)**
- Syphilis**
 antibiotics for, 227 (editorial)
 control of, in female prisoners, 218
 daily procaine penicillin for, compliance with, 127
 early, epidemiology of, 475
 natural history of, 185
 partner notification for, 511, 519 (editorial)
 screening for, 227 (editorial)
 single benzathine penicillin injection for, in pregnancy, 94
 transmission dynamics of, 185
- T**
- Tanzania, sexual transmission of hepatitis B in, 121**
- Tetracycline, *N. gonorrhoeae* resistance to. *See Neisseria gonorrhoeae, drug resistance/susceptibility of***
 in Philippines, 2
- Thailand**
 chlamydial and gonococcal cervicitis in pregnant women in, 495
 commercial sex workers in
 multiple condom use by, 546, 550 (editorial)
 self-medication for STDs in, 593
 gonococcal resistance in, 142
 Thiamphenicol, *N. gonorrhoeae* resistance to, in Thailand, 142
 Travel, casual sex during, high-risk behavior and, 418
 Treatment. *See also Self-treatment*
 delay in seeking, 443
 Treponemal infection, daily procaine penicillin for, compliance with, 127
- Trichomoniasis**
 estrogen replacement therapy and, 543
 oral metronidazole for, vs. clotrimazole vaginal tablets and AVC suppositories, 156
 in pregnancy, 361 (editorial)
 low birth weight and preterm delivery and, 353
 zinc sulfate douche and metronidazole for, 116
- Tuberculosis, STDs and, 8**
- Turkey, chlamydial infection in sex workers in, screening for, 573**
- U**
- Ulcers, genital. *See Genital ulcer disease***
- Unsafe sex practices. *See High-risk behavior; Sexual behavior***
- Urethritis, nongonococcal**
 azithromycin for, 57 (letter)
 in heterosexual men, risk factors for, 449
 in male homosexuals, acquisition of by fellatio, 272
- Urine tests**
 for PCR test for *C. trachomatis*, 343, 429
 for STDs, integrated with behavioral surveys, 299, 552 (letter)
- V**
- Vaccination, for genital herpes, acceptability of, 555**
- Vaginal microbical agents, in vitro evaluation of, organotypic raft cultures for, 69**
- Vaginal smears, self-obtained sequential, utility of, 236**
- Vaginal trichomoniasis. *See Trichomoniasis***
- Vaginosis, bacterial, self-obtained sequential vaginal smears for, utility of, 236**
- Valacyclovir, vs. acyclovir, for first-episode genital herpes, 481**
- Virus culture, vs. PCR, for HSV infection diagnosis, 176**
- Viruses, small, condoms as barriers to, 161**
- W**
- West Africa, *N. gonorrhoeae* resistance in, 32**
- Women**
 casual travel sex in, high-risk behavior and, 418
 commercial sex workers. *See Commercial sex workers*
 HIV infection natural history in, 77
- Z**
- Zimbabwe, STD risk factors in, 528**
- Zinc sulfate douche, with metronidazole, for trichomoniasis, 116**

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970: Section 3685, Title 39, United States Code) Date of Filing—October 1, 1997. Title of Publication—Sexually Transmitted Diseases; Frequency of Issue—10 issues annually; Annual Subscription Price—\$203.00; Location of Known Office of Publication—Lippincott-Raven Publishers, 12107 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of the Headquarters or General Business Office of the Publisher—227 East Washington Square, Philadelphia, PA 19106; Publisher—Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Editor—Julius Schacter, PhD, Room 416/Building #30, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110. Assistant Editor—Jeanne Moncada, Room 416/Building #30, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94119. Owner—American Sexually Transmitted Diseases Association, c/o Denver Public Health, 605 Bannock Street, Denver, CO 80204. Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—none. A. Total no. copies printed (*net press run*), average 2,200, actual 2,400; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 1,422, actual 1,386; C. Total paid circulation, average 1,422, actual 1,386; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 94, actual 85. E. Total distribution (*sum of C and D*), average 1,516, actual 1,471; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 684, actual 929; 2. Returns from news agents, none; G. Total (*sum of E and F—should equal net press runs shown in A*), average 2,200, actual 2,400. I certify that the statements made by me above are correct and complete. Beverly Dietrich, *Circulation Director*.